Healthy
Conditions
Brief summary
The purpose of this study is to elucidate tolerability and effectiveness in consumption of the complex indigestible sugars from dairy products called bovine milk oligosaccharides (BMO) to enrich intestinal microflora toward beneficial populations.
Detailed description
This is a single-blind crossover study designed to determine if BMO at two different doses selectively enrich beneficial bacteria in the human gut and will be tolerated in healthy participants compared with a placebo control supplement. Each participant will consume two sachets of supplement for eleven days, separated by a two-week washout before starting the second and third arms. To determine the effect of dose, the placebo-control supplement will be administered in the first arm, followed by the low and high dose. Participants will collect stool and first morning urine and study personnel collected blood from each participant at baseline (day 0) and at the end (Day 11) of each study arm for all three arms.
Interventions
DIETARY_SUPPLEMENTBovine Milk Oligosaccharide
The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
DIETARY_SUPPLEMENTPlacebo Glucose Polymer
Sponsors
Dairy Research Institute
University of California, Davis
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy men and women aged 18-40 years old * BMI 18-25 * Born by vaginal birth (not C-section) * Breastfed for a minimum of 2 months after birth
Exclusion criteria
* Individuals who regularly consume high fiber cereals or fiber supplements * Individuals who frequently consume yogurt (eligible if willing to refrain consumption during the study period) * Individuals who are lactose intolerant and/or allergic to dairy or wheat * Individuals who use tobacco products * Individuals who are pregnant or lactating * Individuals with a known presence of gastrointestinal/malabsorption disorders or autoimmune disease * Individuals taking prescription or over-the-counter medications that include pre/probiotics, corticosteroids, anti-obesity agents, laxatives, and lipid- altering medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gut microbiota | Change from baseline to day 11 | Gut microbiota will be analyzed for 16s rRNA by next generation sequencing, terminal restriction fragment length polymorphism, and quantitative polymerase chain reaction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Lipid Profile | Day 0 and Day 11 | Fasting plasma lipid profile (total triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol) will be analyzed by enzymatic analysis by UC Davis Pathology Lab. |
| Plasma Glucose | Day 0 and Day 11 | Fasting plasma glucose will be measured by enzyme analysis by UC Davis Pathology Lab. |
| Dietary Macronutrient Intake | Day 0 | Participants will fill out three-day diet records for two weekdays and one weekend before starting each dietary supplemental arm in order to determine if intake of BMO vs. placebo control influences habitual dietary intake. |
| Urinary Metabolites | Days 0, 4, 11 | First morning urine samples will be analyzed by nuclear magnetic resonance spectroscopy. |
| Stool Consistency | Minus Day 7 and Days 0-10 | Participants will fill out the Bristol Stool Scale when they have bowel movements seven days before starting each study arm and daily during each study arm. The discretized visual analog scale 1-7 describes hardness to softness of stool. |
| Fecal BMO | Days 0, 4 and 11 | Measurement of BMOs in feces |
| Fecal Metatranscriptome | Days 0 and 11 | Measurement of fecal metatranscriptome |
| Gut Tolerability | Days Minus 7 and Days 0-10 | Participants will fill out a standardized gut tolerability questionnaire (Pedersen et al., 1997) rating their symptoms of gut and stomach discomfort on a 0-10 discretized visual analog scale daily seven days before starting each arm and on five different occasions on Days 0-10 during each study arm. |
Countries
United States
Outcome results
None listed